-
Wuhan YZY Biopharma Grants Rights to CD3/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China
•
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone…
-
Wuhan YZY Biopharma Presents M701 Interim Results at 2024 ESMO Congress for NSCLC-Related Pleural Effusion
•
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced the presentation of interim analysis results from a Phase Ib clinical study for its investigational drug M701 at the 2024 European Society of Medical Oncology (ESMO) Congress. M701 is a recombinant anti-EpCAM and CD3 human…
-
Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024
•
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), JW Therapeutics (HKG: 2126), and CStone Pharmaceuticals (HKG: 2616), are preparing to present updates on their pipeline products at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting,…
-
Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment
•
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced the enrollment of the first patient in a Phase II clinical study for its investigational drug M701. M701 is a recombinant anti-EpCAM and CD3 human murine chimeric bispecific antibody (BsAb) injection, currently under assessment as…
-
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
•
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs and drug immunotherapies, is poised to raise HKD 220 million (USD 28.4 million) through an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 11,001,200 shares at a price…
